71P Assessment of chest wall toxicity after SABR for early stage lung cancers and osteoporotic risk

Abstract

whilst 72.2% were attributed to other causes, mostly by cardiovascular or respiratory underlying comorbidities. Cough, dermitis or dyspnea were described as mild (G1) acute toxicity in 7 patients. Chronic toxicity was G1 pneumonitis or fibrosis in 11 patients and one patient developed G5 hemoptysis in a local relapse context. Conclusions: Primary lung cancer VMAT based SBRT achieves good local control rates with a tolerable toxicity. Overall survival may be influenced by patient selection.